Edition:
United Kingdom

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,040.00DKK
3:59pm BST
Change (% chg)

kr.-10.00 (-0.95%)
Prev Close
kr.1,050.00
Open
kr.1,041.00
Day's High
kr.1,071.50
Day's Low
kr.1,033.00
Volume
238,146
Avg. Vol
208,229
52-wk High
kr.1,443.00
52-wk Low
kr.880.80

Chart for

About

Genmab A/S is a Denmark-based biotechnology company. It is engaged in the development of differentiated human antibody therapeutics for the treatment of cancer, as well as other medical conditions, such as relapsing remitting multiple sclerosis. Its product pipeline includes a number of research and development projects in... (more)

Overall

Beta: 1.27
Market Cap(Mil.): kr.85,016.77
Shares Outstanding(Mil.): 61.16
Dividend: --
Yield (%): --

Financials

  GEN.CO Industry Sector
P/E (TTM): 63.56 85.68 32.76
EPS (TTM): 21.87 -- --
ROI: 29.46 1.79 14.61
ROE: 29.47 3.28 16.33

Danish biotech Genmab hit by ending of trial using key cancer drug

COPENHAGEN Shares in Danish biotech Genmab fell by as much as 25 percent on Monday after its partner Johnson & Johnson decided to ditch a study using its blockbuster cancer drug.

28 May 2018

Danish biotech Genmab hit by ending of trial using key cancer drug

COPENHAGEN, May 28 Shares in Danish biotech Genmab fell by as much as 25 percent on Monday after its partner Johnson & Johnson decided to ditch a study using its blockbuster cancer drug.

28 May 2018

BRIEF-Genmab: Q1 Net Sales Of Darzalex At $432 Mln

* REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2018

17 Apr 2018

Biotech group Genmab aims to own bigger share of new drug pipeline

COPENHAGEN, April 10 Genmab plans to own a bigger share of drugs in its early-stage pipeline as Europe's biggest biotechnology company prepares to reduce its reliance on a blockbuster cancer drug, marketed by partner Johnson & Johnson.

10 Apr 2018

Earnings vs. Estimates